Instrument Inactif

Autres langues Flying Brands Ltd. London S.E.

Actions

IQ-AI subsidiary opens expanded access programme	25/06
IQ-AI Says Brain Cancer Drug Delays Disease Progression in Early-stage Study	14/06
IQ-AI team begins defining phase 2 protocol for oral gallium maltolate	14/06
IQ-AI Ltd. Provides Update on Phase 1 Update	14/06
Celadon ships to US; Oxford BioDynamics-Goodbody pact	23/05
IQ-AI subsidiary gets second FDA rare paediatric disease designation	20/05
IQ-AI's Imaging Biometrics Gets Second Rare Disease Designation for Drug Candidate	20/05
Ingenta trades in line; Triple Point Social NAV up	17/05
IQ-AI Unit Delivers Software to Insel Gruppe	17/05
IQ-AI subsidiary gets rare paediatric disease designation FDA	10/05
IQ-AI's Imaging Biometrics Obtains Rare Pediatric Disease Designation for Lead Drug Candidate	10/05
EARNINGS AND TRADING: Trident Royalties swings to profit	02/05
IQ-AI Limited Provides Revenue Guidance for the Financial Year 2024	29/04
IQ-AI Limited Reports Earnings Results for the Full Year Ended December 31, 2023	29/04
IQ-AI advances glioblastoma clinical trial, eyes phase two in 2025	26/02
IQ-AI's Broker Exercises Option to Buy Shares in Placing	26/02
IQ-AI Plans Share Placing to Advance Oral Anti-tumor Agent Development	22/02
IQ-AI shares sink on discounted placing fundraise	22/02
IQ-AI Unit to Revise, Resubmit Pediatric Rare Disease Designation Application After US FDA Feedback	09/02
IQ-AI subsidiary asked by FDA to resubmit and modify application	09/02

Aucun résultat pour cette recherche